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Abstract 
Background: Performing cancer research relies on substantial financial investment, and contributions in time and 
effort from patients. It is therefore important that this research has real life impacts which are properly evaluated. The 
optimal approach to cancer research impact evaluation is not clear. The aim of this study was to undertake a sys-
tematic review of review articles that describe approaches to impact assessment, and to identify examples of cancer 
research impact evaluation within these reviews.
Methods: In total, 11 publication databases and the grey literature were searched to identify review articles address-
ing the topic of approaches to research impact assessment. Information was extracted on methods for data collection 
and analysis, impact categories and frameworks used for the purposes of evaluation. Empirical examples of impact 
assessments of cancer research  were identified from these literature reviews. Approaches used in these examples were 
appraised, with a reflection on which methods would be suited to cancer research  impact evaluation going forward.
Results: In total, 40 literature reviews were identified. Important methods to collect and analyse data for impact 
assessments were surveys, interviews and documentary analysis. Key categories of impact spanning the reviews were 
summarised, and a list of frameworks commonly used for impact assessment was generated. The Payback Framework 
was most often described. Fourteen examples of impact evaluation for cancer research  were identified. They ranged 
from those assessing the impact of a national, charity-funded portfolio of cancer research to the clinical practice 
impact of a single trial. A set of recommendations for approaching cancer research impact assessment was generated.
Conclusions: Impact evaluation can demonstrate if and why conducting cancer research  is worthwhile. Using a 
mixed methods, multi-category assessment organised within a framework, will provide a robust evaluation, but the 
ability to perform this type of assessment may be constrained by time and resources. Whichever approach is used, 
easily measured, but inappropriate metrics should be avoided. Going forward, dissemination of the results of cancer 
research impact assessments will allow the cancer research  community to learn how to conduct these evaluations.
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Background
Cancer research attracts substantial public funding glob-
ally. For example, the National Cancer Institute (NCI) in 
the United States of America (USA) had a 2020 budget 
of over $6 billion United States (US) dollars. In addition 
to public funds, there is also huge monetary investment 
from private pharmaceutical companies, as well as altru-
istic investment of time and effort to participate in cancer 
research from patients and their families. In the United 
Kingdom (UK), over 25,000 patients were recruited to 
cancer trials funded by one charity (Cancer Research UK 
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(CRUK)) alone in 2018 [1]. The need to conduct research 
within the field of oncology is an ongoing priority because 
cancer is highly prevalent, with up to one in two people 
now having a diagnosis of cancer in their lifetime [2, 3], 
and despite current treatments, mortality and morbidity 
from cancer are still high [2].
In the current era of increasing austerity, there is a 
desire to ensure that the money and effort to conduct 
any type of research delivers tangible downstream ben-
efits for society with minimal waste [4–6]. These wider, 
real-life benefits from research are often referred to as 
research impact. Given the significant resources required 
to conduct cancer research in particular, it is reasonable 
to question if this investment is leading to the longer-
term benefits expected, and to query the opportunity 
cost of not spending the same money directly within 
other public sectors such as health and social care, the 
environment or education.
The interest in evaluating research impact has been ris-
ing, partly driven by the actions of national bodies and 
governments. For example, in 2014, the UK government 
allocated its £2 billion annual research funding to higher 
education institutions, in part based on an assessment of 
the impact of research performed by each institution in 
an assessment exercise known as the Research Excellence 
Framework (REF). The proportion of funding dependent 
on impact assessment will increase from 20% in 2014, to 
25% in 2021[7].
Despite the clear rationale and contemporary interest 
in research impact evaluation, assessing the impact of 
research comes with challenges. First, there is no single 
definition of what research impact encompasses, with 
potential differences in the evaluation approach depend-
ing on the definition. Second, despite the recent surge of 
interest, knowledge of how best to perform assessments 
and the infrastructure for, and experience in doing so, 
are lagging [6, 8, 9]. For the purposes of this review, the 
definition of research impact given by the UK Research 
Councils is used (see Additional file 1 for full definition). 
This definition was chosen because it takes a broad per-
spective, which includes academic, economic and soci-
etal views of research impact [10].
There is a lack of clarity on how to perform research 
impact evaluation, and this extends to cancer research. 
Although there is substantial interest from cancer 
funders and researchers [11], this interest is not accom-
panied by instruction or reflection on which approaches 
would be suited to assessing the impact of cancer 
research specifically. In a survey of Australian can-
cer researchers, respondents indicated that they felt a 
responsibility to deliver impactful research, but that eval-
uating and communicating this impact to stakeholders 
was difficult. Respondents also suggested that the types 
of impact expected from research, and the approaches 
used, should be discipline specific [12]. Being cognisant 
of the discipline specific nature of impact assessment, 
and understanding the uniqueness of cancer research in 
approaching such evaluations, underpins the rationale 
for this study.
The aim of this study was to explore approaches to 
research impact assessment, identify those  approaches 
that have been used previously for cancer research, and 
to use this information to make recommendations for 
future evaluations. For the purposes of this study, can-
cer research included both basic science and applied 
research, research into any malignant disease, concerning 
paediatric or adult cancer, and studies spanning nursing, 
medical, public health elements of cancer research.
The study objectives were to:
 i. Identify existing literature reviews that report 
approaches to research impact assessment and 
summarise these approaches.
 ii. Use these literature reviews to identify examples of 
cancer research impact evaluations, describe the 
approaches to evaluation used within these stud-
ies, and compare them to those described in the 
broader literature.
This approach was taken because of the anticipated 
challenge of conducting a primary review of empiri-
cal examples of cancer research impact evaluation, and 
to allow a critique of empirical studies in the context 
of lessons learnt from the wider literature. A primary 
review would have been difficult because examples of 
cancer research impact evaluation, for example, the 
assessment of research impact on clinical guidelines 
[13], or clinical practice [14–16], are often not cat-
egorised in publication databases under the umbrella 
term of research impact. Reasons for this are the lack 
of medical subject heading (MeSH) search term relating 
to research impact assessment and the differing defini-
tions for research impact. In addition, many authors do 
not recognise their evaluations as sitting within the dis-
cipline of research impact assessment, which is a novel 
and emerging field of study.
Methods
General approach
A systematic search of the literature was performed to 
identify existing reviews of approaches to assess the 
impact of research. No restrictions were placed on the 
discipline, field, or scope (national/global) of research 
for this part of the study. In the second part of this study, 
the reference lists of the literature reviews identified were 
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searched to find empirical examples of the evaluation of 
the impact of cancer research specifically.
Data sources and searches
For the first part of the study, 11 publication databases 
and the grey literature from January 1998 to May 2019 
were searched. The electronic databases were Med-
line, Embase, Health Management and Policy Database, 
Education Resources Information Centre, Cochrane, 
Cumulative Index of Nursing and Allied Health Litera-
ture, Applied Social Sciences Index and Abstract, Social 
Services Abstracts, Sociological Abstracts, Health Busi-
ness Elite and Emerald. The search strategy specified that 
article titles must contain the word “impact”, as well as 
a second term indicating that the article described the 
evaluation of impact, such as “model” or “measurement” 
or “method”. Additional file 1 provides a full list of search 
terms. The grey literature was searched using a proforma. 
Keywords were inserted into the search function of web-
sites listed on the proforma and the first 50 results were 
screened. Title searches were performed by either a spe-
cialist librarian or the primary researcher (Dr. C Hanna). 
All further screening of records was performed by the 
primary researcher.
Following an initial title screen, 800 abstracts were 
reviewed and 140 selected for full review. Articles were 
kept for final inclusion in the study by assessing each arti-
cle against specific inclusion criteria (Additional file  1). 
There was no assessment of the quality of the included 
reviews other than to describe the search strategy used. If 
two articles drew primarily on the same review but con-
tributed a different critique of the literature or methods 
to evaluate impact, both were kept. If a review article was 
part of a grey literature report, for example a thesis, but 
was also later published in a journal, the journal article 
only was kept. Out of 140 articles read in full, 27 met the 
inclusion criteria and a further 13 relevant articles were 
found through reference list searching from the included 
reviews [17].
For the second part of the study, the reference lists 
from the literature reviews were manually screened [17] 
(n = 4479 titles) by the primary researcher to identify 
empirical examples of assessment of the impact of can-
cer research. Summary tables and diagrams from the 
reviews were also searched using the words “cancer” and 
“oncology” to identify relevant articles that may have 
been missed by reference list searching. After removal of 
duplicates, 57 full articles were read and assessed against 
inclusion criteria (Additional file  1). Figure  1 shows the 
search strategy for both parts of the study according to 
the guidelines for preferred reporting items for system-
atic reviews and meta-analysis (PRISMA) [18].
Data extraction and analysis
A data extraction form produced in  Microsoft® Word 
2016 was used to collect details for each literature 
review. This included year of publication, location of pri-
mary author, research discipline, aims of the review as 
described by the authors and the search strategy (if any) 
used. Information on approaches to impact assessment 
was extracted under three specific themes which had 
been identified from a prior scoping review as impor-
tant factors when planning and conducting research 
impact evaluation. These themes were: (i) categorisation 
of impact into different types depending on who or what 
is affected by the research (the individuals, institutions, 
or parts of society, the environment), and how they are 
affected (for example health, monetary gain, sustainabil-
ity) (ii) methods of data collection and analysis for the 
purposes of evaluation, and (iii) frameworks to organise 
and communicate research impact. There was space to 
document any other key findings the researcher deemed 
important. After data extraction, lists of commonly 
described categories, methods of data collection and 
analysis, and frameworks were compiled. These lists were 
tabulated or presented graphically and narrative analysis 
was used to describe and discuss the approaches listed.
For the second part of the study, a separate data extrac-
tion form produced in  Microsoft® Excel 2016 was used. 
Basic information on each study was collected, such as 
year of publication, location of primary authors, research 
discipline, aims of evaluation as described by the authors 
and research type under assessment. Data was also 
extracted from these empirical examples using the same 
three themes as outlined above, and the approaches used 
in these studies were compared to those identified from 
the literature reviews. Finally, a set of recommendations 
for future evaluations of cancer research impact were 
developed by identifying the strengths of the empiri-
cal examples and using the lists generated from the first 
part of the study to identify improvements that could be 
made.
Results
Part one: Identification and analysis of literature reviews 
describing approaches to research impact assessment
Characteristics of included literature reviews
Forty literature reviews met the pre-specified inclusion 
criteria and the characteristics of each review are out-
lined in Table 1. A large proportion (20/40; 50%) were 
written by primary authors based in the UK, followed 
by the USA (5/40; 13%) and Australia (5/40; 13%), with 
the remainder from Germany (3/40; 8%), Italy (3/40; 
8%), the Netherlands (1/40; 3%), Canada (1/40; 3%), 
France (1/40; 3%) and Iran (1/40; 3%). All reviews were 
published since 2003, despite the search strategy dating 
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Fig. 1 Search strategies for this study
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from 1998. Raftery et  al. 2016 [19] was an update to 
Hanney et al. 2007 [20] and both were reviews of stud-
ies assessing research impact relevant to a programme 
of health technology assessment research. The narra-
tive review article by Greenhalgh et al. [21] was based 
on the same search strategy used by Raftery et al. [19].
Approximately half of the reviews (19/40; 48%) 
described approaches to evaluate research impact with-
out focusing on a specific discipline and nearly the 
same amount (16/40; 40%) focused on evaluating the 
impact of health or biomedical research. Two reviews 
looked at approaches to impact evaluation for environ-
mental research and one focused on social sciences and 
humanities research. Finally, two reviews provided a 
critique of impact evaluation methods used by differ-
ent countries at a national level [22, 23]. None of these 
reviews focused specifically on cancer research.
Twenty-five reviews (25/40; 63%) specified search cri-
teria and 11 of these included a PRISMA diagram. The 
articles that did not outline a search strategy were often 
expert reviews of the approaches to impact assess-
ment methods and the authors stated they had chosen 
the articles included based on their prior knowledge 
of the topic. Most reviews were found by search-
ing traditional publication databases, however seven 
(7/40; 18%) were found from the grey literature. These 
included four reports written by an independent, not-
for-profit research institution (Research and Develop-
ment (RAND) Europe) [23–26], one literature review 
which was part of a Doctor of Philosophy (Ph.D) thesis 
[27], a literature review informing a quantitative study 
[28] and a review that provided background informa-
tion for a report to the UK government on the best use 
of impact metrics [29].
Key findings from the reviews: approaches to research impact 
evaluation
 i. Categorisation of impact for the purpose of impact 
assessment
 Nine reviews attempted to categorise the type of 
research impact being assessed according to who 
or what is affected by research, and how they are 
affected. In Fig. 2, colour coding was used to iden-
tify overlap between impact types identified in 
these reviews to produce a summary list of seven 
main impact categories.
 The first two categories of impact refer to the immedi-
ate knowledge produced from research and the 
contribution research makes to driving innovation 
and building capacity for future activities within 
research institutions. The former is often referred 
to as the academic impact of research. The aca-
demic impact of cancer research may include the 
knowledge gained from conducting experiments 
or performing clinical trials that is subsequently 
disseminated via journal publications. The latter 
may refer to securing future funding for cancer 
research, providing knowledge that allows develop-
ment of later phase clinical trials or training cancer 
researchers of the future.
 The third category identified was the impact of research 
on policy. Three of the review articles included in 
this overview specifically focused policy impact 
evaluation [30–32]. In their review, Hanney 
et  al. [30] suggested that policy impact (of health 
research) falls into one of three sub-categories: 
impact on national health policies from the govern-
ment, impact on clinical guidelines from profes-
sional bodies, and impact on local health service 
policies. Cruz Rivera and colleagues [33] specifi-
cally distinguished impact on policy making from 
impact on clinical guidelines, which they described 
under health impact. This shows that the lines 
between categories will often blur.
 Impact on health was the next category identified and 
several of the reviews differentiated health sec-
tor impact from impact on health gains. For can-
cer research, both types of health impact will be 
important given that it is a health condition which 
is a major burden for healthcare systems and the 
patients they treat. Economic impact of research 
was the fifth category. For cancer research, there 
is likely to be close overlap between healthcare 
system and economic impacts because of the high 
cost of cancer care for healthcare services globally.
 In their 2004 article, Buxton et al. [34] searched the lit-
erature for examples of the evaluation of economic 
return on investment in health research and found 
four main approaches, which were referenced in 
several later reviews [19, 25, 35, 36]. These were 
(i) measuring direct cost savings to the health-care 
system, (ii) estimating benefits to the economy 
from a healthy workforce, (iii) evaluating benefits 
to the economy from commercial development 
and, (iv) measuring the intrinsic value to society 
of the health gain from research. In a later review 
[25], they added an additional approach of estimat-
ing the spill over contribution of research to the 
Gross Domestic Product (GDP) of a nation.
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 The final category was social impact. This term was 
commonly used in a specific sense to refer to 
research improving human rights, well-being, 
employment, education and social inclusion [33, 
37]. Two of the reviews which included this cat-
egory focused on the impact of non-health related 
research (social sciences and agriculture), indicat-
ing that this type of impact may be less relevant or 
less obvious for health related disciplines such as 
oncology. Social impact is distinct from the term 
societal impact, which was used in a wider sense to 
describe impact that is external to traditional aca-
demic benefits [38, 39]. Other categories of impact 
identified that did not show significant overlap 
between the reviews included cultural and tech-
nological impact. In two of the literature reviews 
[33, 40], the authors provided a list of indicators 
of impact within each of their categories. In the 
review by Thonon et al. [40], only one (1%) of these 
indicators was specific to evaluating the impact of 
cancer research.
 ii. Methods for data collection and analysis
 In total, 36 (90%) reviews discussed methods to collect 
or analyse the data required to conduct an impact 
evaluation. The common methods described, and 
the  strengths and weaknesses of each approach, are 
shown in Additional file 2: Table S1. Many authors 
advocated using a mixture of methods and in par-
ticular, the triangulation of surveys, interviews (of 
researchers or research users), and documentary 
analysis [20, 30–32]. A large number of reviews 
cautioned against the use of quantitative metrics, 
such as bibliometrics, alone [29, 30, 41–48]. Con-
cerns included that these metrics were often not 
designed to be comparable between research pro-
grammes [49], their use may  incentivise research-
ers to focus on quantity rather than quality [42], 
and these metrics could be gamed and used in the 
wrong context to make decisions about researcher 
funding, employment and promotion [41, 43, 45].
 Several reviews explained that the methods for data col-
lection and analysis chosen for impact evaluation 
depended on both the unit of research under analy-
sis and the rationale for the impact analysis [23, 
24, 26, 31, 36, 50, 51]. Specific to cancer research, 
Brutscher 2008 Banzi 2011 Moed 2015 Polli 2015 Thonon 2015 Raery 2016 Cruz Rivera 2017 Reale 2017 Weisshuhn 2018
Scienfic (Target group: 
research community) Advancing knowledge 
Scienfic impact:
Knowledge growth
Knowledge producon and 
research targeng Research acvity
Mul-dimensional 
(health gains, economic, 
policy)
Primary research related 
impact Scienfic Economic
Social (Target group: 
public sector) Capacity building 
Scienfic impact: 
Research networks Capacity building 
Scienfic producon and 
impact Economic impacts
Influence on policy 
making Social Social
Economic (Target group: 
industry/companies)




Innovave and economic 
impact Collaboraon
Policy impacts, including 
clinical polices
Health and health 
systems impact Polical Environmental
Cultural (Target group: 
General Public)
Health and health sector 
benefits Societal impact: Social




Health related and 
societal impact Sustainability




Policy and public services 










1. Immediate knowledge (including 
disseminaon)
2. Capacity building for future 
research
3. Policy impact
4. Health sector benefit
5. Health gains for paents and the public  
6. Economic impact
7. Social impact
Other e.g. cultural, technological. 
Fig. 2 Categories of impact identified in the included literature reviews
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the unit of analysis may be a single clinical trial 
or a programme of trials, research performed at 
a cancer centre or research funded by a specific 
institution or charity. The rationale for research 
impact assessment was categorised in multiple 
reviews under four headings (“the 4 As”): advo-
cacy, accountability, analysis and allocation [19, 20, 
23, 24, 30–33, 36, 46, 52, 53]. Finally, Boaz and col-
leagues found that there was a lack of information 
on the cost-effectiveness of research impact evalu-
ation methods but suggested that pragmatic, but 
often cheaper approaches to evaluation, such as 
surveys, were least likely to give in depth insights 
into the processes through which research impact 
occurred [31].
 iii. Using a framework within a research impact evalu-
ation
 Applied to research impact evaluation, a framework 
provides a way of organising collected data, which 
encourages a more objective and structured evalu-
ation than would be possible with an ad hoc anal-
ysis. In total, 27 (68%) reviews discussed the use 
of a framework in this context. Additional file  2: 
Table S2 lists the frameworks mentioned in three or 
more of the included reviews. The most frequently 
described framework was the Payback Framework, 
developed by Buxton and Hanney in 1996 [54], and 
many of the other frameworks identified reported 
that they were developed by adapting key elements 
of the Payback framework. None of the frameworks 
identified were specifically developed to assess the 
impact of cancer research, however several were 
specific to health research. The unit of cancer 
research being evaluated  will dictate the most suit-
able framework to use in any evaluation. The unit of 
research most suited to each framework is outlined 
in Additional file 2: Table S2.
Additional findings from the included reviews
The challenges of research impact evaluation were com-
monly discussed in these reviews. Several mentioned that 
the time lag [24, 25, 33, 35, 38, 46, 50, 53, 55] between 
research completion and impact occurring should influ-
ence when an impact evaluation is carried out: too early 
and impact will not have occurred, too late and it is dif-
ficult to link impact to the research in question. This 
overlapped with the challenge of attributing impact to a 
particular piece of research [24, 26, 33–35, 37–39, 46, 50, 
56]. Many authors argued that the ability to show attribu-
tion was inversely related to the time since the research 
was carried out [24, 25, 31, 46, 53].
Part II: Empirical examples of cancer research impact 
evaluation
Study characteristics
In total, 14 empirical impact evaluations relevant to can-
cer research were identified from the references lists of 
the literature reviews included in the first part of this 
study. These empirical studies were published between 
1994–2015 by primary authors located in the UK (7/14; 
50%), USA (2/14; 14%), Italy (2/14; 14%), Canada (2/14; 
14%) and Brazil (1/14; 14%). Table  2 lists these studies 
with the rationale for each assessment (defined using the 
“4As”), the unit of analysis of cancer research evaluated 
and the main findings from each evaluation. The catego-
ries of impact evaluated, methods of data collection and 
analysis, and impact frameworks utilised are also sum-
marised in Table 2 and discussed in more detail below.
Approaches to cancer research impact evaluation used 
in empirical studies
 i. Categories of impact evaluated in cancer research 
impact assessments
 Several of the empirical studies focused on academic 
impact. For example, Ugolini and colleagues evalu-
ated scholarly outputs from one cancer research 
centre in Italy [57] and in a second study looked 
at the academic impact of cancer research from 
European countries [58]. Saed et al. [59] used sub-
missions to an international cancer conference 
(American Society of Clinical Oncology (ASCO)) 
to evaluate the dissemination of cancer research 
to the academic community, and Lewison and col-
leagues [60–63] assessed academic, as well as pol-
icy impact and dissemination of cancer research 
findings to the lay media.
 The category of the health impact was also commonly 
evaluated, with particular focus on the assess-
ment of survival gains. Life years gained or deaths 
averted [64], life expectancy gains [65] and years 
of extra survival [66] were all used as indica-
tors of the health impact attributable to cancer 
research. Glover and colleagues [67] used a meas-
ure of health utility, the quality adjusted life year 
(QALY), which combines both survival and quality 
of life assessments. Lakdawalla and colleagues [66] 
considered the impact of both research on can-
cer screening and treatments, and concluded that 
survival gains were 80% attributable to treatment 
improvement. In contrast, Glover and colleagues 
[67] acknowledged the importance of improved 
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cancer therapies due to research but also highlight 
the major impacts from research around smok-
ing cessation, as well as cervical and bowel cancer 
screening. Several of these studies that assessed 
health impact, also used the information on health 
gains to assess the economic impact of the same 
research [64–67].
 Finally, two studies [68, 69] performed multi-dimen-
sional research impact assessments, which incor-
porated nearly all of the seven categories of impact 
identified from the previous literature (Fig.  2). In 
their assessment of the impact of research funded 
by one breast cancer charity in Australia, Donovan 
and colleagues [69] evaluated academic, capac-
ity building, policy, health, and wider economic 
impacts. Montague and Valentim [68] assessed the 
impact of one randomised clinical trial (MA17) 
which investigated the use of a hormonal medi-
cation as an adjuvant treatment for patients with 
breast cancer. In their study, they assessed the dis-
semination of research findings, academic impact, 
capacity building for future trials and international 
collaborations, policy citation, and the health 
impact of decreased breast cancer recurrence 
attributable to the clinical trial.
 ii. Methods of data collection and analysis for cancer 
research impact evaluation
 Methods for data collection and analysis used in these 
studies aligned with the categories of impact 
assessed. For example, studies assessing academic 
impact used traditional bibliometric searching of 
publication databases and associated metrics. Ugo-
lini et al. [57] applied a normalised journal impact 
factor to publications from a cancer research centre 
as an indicator of the research quality and produc-
tivity from that centre. This analysis was adjusted 
for the number of employees within each depart-
ment and the scores were used to apportion 20% 
of future research funding. The same bibliometric 
method of analysis was used in a second study by 
the same authors to compare and contrast national 
level, cancer research efforts across Europe [58]. 
They assessed the quantity and the mean impact 
factor of the journals for publications from each 
country and compared this to the location-spe-
cific population and GDP. A similar approach was 
used for the manual assessment of 10% of cancer 
research abstracts submitted to an international 
conference (ASCO) between 2001–2003 and 
2006–2008 [59]. These authors examined if the 
location of authors affected the likelihood of the 
abstract being presented orally, as a face-to-face 
poster or online only.
 Lewison and colleagues, who performed four of the 
studies identified [60–63], used a different bib-
liometric method of publication citation count 
to analyse the dissemination, academic, and pol-
icy impact of cancer research. The authors also 
assigned a research level to publications to differ-
entiate if the research was a basic science or clini-
cal cancer study by coding the words in the title 
of each article or the journal in which the paper 
was published. The cancer research types assessed 
by these authors included cancer research at a 
national level for two different countries (UK and 
Russia) and research performed by cancer centres 
in the UK.
 To assess policy impact these authors extracted journal 
publications from cancer clinical guidelines and for 
media impact they looked at publications cited in 
articles stored within an online repository from a 
well-known UK media organisation (British Broad-
casting Co-operation). Interestingly, most of the 
cancer research publications contained in guide-
lines and cited in the UK media were clinical stud-
ies whereas a much higher proportion published 
by UK cancer centres were basic science studies. 
These authors also identified that funders of cancer 
research played an critical role as commentators 
to explain the importance of the research in the 
lay media. The top ten most frequent commenta-
tors (commenting on > 19 media articles (out of 
725) were all representatives from the UK charity 
CRUK.
 A combination of clinical trial findings and documen-
tary analysis of large data repositories were used to 
estimate health system or health impact. In their 
study, Montague and Valentim [68] cited the effect 
size for a decrease in cancer recurrence from a clin-
ical trial and implied the same health gains would 
be expected in real life for patients with breast can-
cer living in Canada. In their study of the impact of 
charitable and publicly funded cancer research in 
the UK, Glover et  al. [67] used CRUK and Office 
for National Statistics (ONS) cancer incidence 
data, as well as national hospital databases listing 
episodes of radiotherapy delivered, number of can-
cer surgeries performed and systemic anti-cancer 
treatments prescribed, to evaluate changes in prac-
tice attributable to cancer research. In their USA 
perspective study, Lakdawalla et  al. [66] used the 
population-based Surveillance, Epidemiology and 
End Results Program (SEER) database to evaluate 
the number of patients likely to be affected by the 
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implementation of cancer research findings [66]. 
Survival calculations from clinical trials were also 
applied to population incidence estimates to pre-
dict the scale of survival gain attributable to cancer 
research [64, 66].
 The methods of data collection and analysis used for 
economic evaluations aligned with the categories 
of assessment identified by Buxton in their 2004 
literature review [34]. For example, three studies 
[65–67] estimated direct healthcare cost savings 
from implementation of cancer research. This was 
particularly relevant in one ex-ante assessment 
of the potential impact of a clinical trial testing 
the equivalence of using less intensive follow up 
for patients following cancer surgery [65]. These 
authors assessed the number of years it would take 
(“years to payback”) of implementing the hypothet-
ical clinical trial findings to outweigh the money 
spent developing and running the trial. The return 
on investment calculation was performed by esti-
mating direct cost savings to the healthcare system 
by using less intensive follow up without any detri-
ment to survival.
 The second of Buxton’s categories was an estima-
tion of productivity loss using the human capital 
approach. In this method, the economic value of 
survival gains from cancer research are calculated 
by measuring the monetary contribution from 
patients surviving longer who are of working age. 
This approach was used in two studies [64, 66] and 
in both, estimates of average income (USA) were 
utilised. Buxton’s fourth category, an estimation 
of an individual’s willingness to pay for a statisti-
cal life, was used in two assessments [65, 66], and 
Glover and colleagues [67] adapted this method, 
placing a monetary value on the opportunity cost 
of QALYs forgone in the UK health service within a 
fixed budget [70]. One of the studies that used this 
method identified that there may be differences in 
how patients diagnosed with distinct cancer types 
value the impact of research on cancer specific sur-
vival [66]. In particular, individuals with pancreatic 
cancer seemed to be willing to spend up to 80% of 
their annual income for the extra survival attribut-
able to implementation of cancer research findings, 
whereas this fell to below 50% for breast and colo-
rectal cancer. Only one of the studies considered 
Buxton’s third category of benefits to the economy 
from commercial development [66]. These authors 
calculated the gain to commercial companies from 
sales of on-patent pharmaceuticals and concluded 
that economic gains to commercial producers were 
small relative to gains from research experienced 
by cancer patients.
 The cost estimates used in these impact evaluations 
came from documentary analysis, clinical trial pub-
lications, real-life data repositories, surveys, and 
population average income estimates. For example, 
in one study, cost information from NCI trials was 
supplemented by using a telephone phone survey 
to pharmacies, historical Medicare documents and 
estimates of the average income from the 1986 US 
Bureau of the Census Consumer Income [64]. In 
their study, Coyle et  al. [65] costed annual follow 
up and treatment for cancer recurrence based on 
the Ontario Health Insurance plan, a cost model 
relevant to an Ottawa hospital and cost estimates 
from Statistics Canada [71]. The data used to cal-
culate the cost of performing cancer research was 
usually from funding bodies and research institu-
tions. For example, charity reports and Canadian 
research institution documents were used to esti-
mate that it costs the National Cancer Institute 
in Canada $1500 per patient accrued to a clinical 
trial [65]. Government research investment outgo-
ings were used to calculate that $300 billion was 
spent on cancer research in the USA from 1971 to 
2000, 25% of which was contributed by the NCI 
[66] and that the NCI spent over $10 million USD 
in the 1980s to generate the knowledge that adju-
vant chemotherapy was beneficial to colorectal 
cancer patients [64]. Charity and research institu-
tion spending reports, along with an estimation of 
the proportion of funds spent specifically on cancer 
research, were used to demonstrate £15 billion of 
UK charity and public money was spent on cancer 
research between 1970 and 2009 [67].
 Lastly, the two studies [68, 69] which adopted a multi-
category approach to impact assessment used the 
highest number and broadest range of methods 
identified from the previous literature (Additional 
file 2: Table S1). The methods utilised included sur-
veys and semi-structured telephone interviews 
with clinicians, documentary analysis of funding 
and project reports, case studies, content analy-
sis of media release, peer review, bibiliometrics, 
budget analysis, large data repository review, and 
observations of meetings.
 iii. Frameworks for cancer research impact evaluation
 Only two of the empirical studies identified used an 
impact framework. Unsurprisingly, these were 
also the studies that performed a multi-category 
assessment and used the broadest range of meth-
ods within their analyses. Donovan et al. [69] used 
the Payback framework (Additional file 2: Table S2) 
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to guide the categories of impact assessed and the 
questions in their researcher surveys and inter-
views. They also reported the results of their evalu-
ation using the same categories: from knowledge 
production, through capacity building to health 
and wider economic impacts. Montague and Val-
entim [68] used the Canadian Academy Health 
Services (CAHS) Framework (Additional file  2: 
Table  S2). Rather than using the framework in 
it is original form, they arranged impact indica-
tors from the CAHS framework within a hierar-
chy to illustrate impacts occurring over time. The 
authors distinguished short term, intermediate and 
longer-term changes resulting from one clinical 
cancer trial, aligning with the concept of categoris-
ing impacts based on when they occur, which was 
described in one of the literature reviews identified 
in the first part of this study [33].
 Lastly, the challenges of time lags and attribution of 
impact were identified and addressed by sev-
eral of these empirical studies. Lewison and col-
leagues tracked the citation of over 3000 cancer 
publications in UK cancer clinical guidelines over 
time [61], and in their analysis Donovan et al. [69] 
explicitly acknowledged that the short time frame 
between their analysis and funding of the research 
projects under evaluations was likely to under-esti-
mate the impact achieved. Glover et  al. [67] used 
bibliometric analysis of citations in clinical cancer 
guidelines to estimate the average time from pub-
lication to clinical practice change (8  years). They 
added 7  years to account for the time between 
funding allocation and publication of research 
results giving an overall time lag from funding can-
cer research to impact of 15  years. The challenge 
of attribution was addressed in one study by using 
a time-line to describe impacts occurring at dif-
ferent time-points but linking back to the original 
research in question [68]. The difficultly of esti-
mating time lags and attributing impact to cancer 
research were both specifically addressed in a com-
panion study [72] to the one conducted by Glover 
and colleagues. In this study, instead of quanti-
fying the return on cancer research investment, 
qualitative methods of assessment were used. This 
approach  identified factors that enhanced and 
accelerated the process of impact occurring and 
helped to provide a narrative to link impacts to 
research.
Discussion
This study has identified several examples of the evalua-
tion of the impact of cancer research. These evaluations   
were performed over three decades, and mostly assessed 
research performed in high-income countries. Justification 
for the approach to searching the literature used   in this 
study is given by looking at the titles of the articles iden-
tified. In only 14% (2/14) was the word “impact” included, 
suggesting that performing a search for empirical exam-
ples of cancer research impact evaluation using traditional 
publication databases would have been challenging. Fur-
thermore, all the studies identified were included within 
reviews of approaches to research impact evaluation, which 
negated the subjective decision of whether the studies com-
plied with a particular definition of research impact.
Characteristics of research that were specifically rele-
vant to cancer studies can be identified from these impact 
assessments. Firstly, many of these evaluations acknowl-
edged the contribution of both basic and applied studies 
to the body of cancer research, and several studies cat-
egorised research publications based on this distinction. 
Second, the strong focus on health impact and the expec-
tation that cancer research will improve health was not 
surprising. The focus on survival in particular, especially 
in economic studies looking at the value of health gains, 
reflects the high mortality of cancer as a disease entity. 
This contrasts with similar evaluations of musculoskel-
etal or mental health research, which have focused on 
improvements in morbidity [73, 74]. Third, several stud-
ies highlighted the distinction between research looking 
at different aspects of the cancer care continuum; from 
screening, prevention and diagnosis, to treatment and 
end of life care. The division of cancer as a disease entity 
by the site of disease was also recognised. Studies that 
analysed the number of patients diagnosed with cancer, 
or population-level survival gains, often used site-specific 
cancer incidence and other studies evaluated research 
relating to only one type of cancer [64, 65, 68, 69]. Lastly, 
the empirical examples of cancer research impact identi-
fied in this study confirm the huge investment into can-
cer research that exists, and the desire by many research 
organisations and funders to quantify a rate of return on 
that investment. Most of these studies concluded that 
cancer research investment far exceeded expectations of 
the return on investment. Even using the simple measure 
of future research grants attracted by researchers funded 
by one cancer charity, the monetary value of these grants 
outweighed the initial investment [69].
There were limitations in the approaches to impact 
evaluation used in these studies which were recognised 
by reflecting on the findings from the broader litera-
ture. Several studies assessed academic impact in isola-
tion, and studies using the journal impact factor or the 
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location of authors on publications were limited in the 
information they provided. In particular, using the jour-
nal impact factor (JIF) to allocate funding research which 
was used in one study,  is now outdated and controver-
sial. The policy impact of cancer research was commonly 
evaluated by using clinical practice guidelines, but other 
policy types that could be used in impact assessment [30], 
such as national government reports or local guidelines, 
were rarely used. In addition, using cancer guidelines as 
a surrogate for clinical practice change and health service 
impact could have drawbacks. For example, guidelines can 
often be outdated, irrelevant or simply not used by cancer 
clinicians and in addition, local hospitals often have their 
own local clinical guidelines, which may take precedent 
over national documents. Furthermore, the other aspects 
of policy impact described in the broader literature [30], 
such as impact on policy agenda setting and implemen-
tation, were rarely assessed. There were also no specific 
examples of social, environmental or cultural impacts and 
very few of the studies mentioned wider economic ben-
efits from cancer research, such as spin out companies 
and patents. It may be that these types of impact were less 
relevant to cancer research being assessed, however unex-
pected impacts may have be identified if they were con-
sidered at the time of impact evaluation.
Reflecting on how the methods of data collection and 
analysis used in these studies aligned with those listed 
in Additional file  2: Table  S1 bibliometrics, alternative 
metrics (media citation), documentary analysis, surveys 
and economic approaches were often used. Methods less 
commonly adopted were interviews, using a scale and 
focus groups. This may have been due to the time and 
resource implications of using qualitative techniques and 
more in depth analysis, or a lack of awareness by authors 
regarding the types of scales that could be used. An 
example of a scale that could be used to assess the impact 
of research on policy is provided in one of the literature 
reviews identified [30]. The method of collecting expert 
testimony from researchers was utilised in the studies 
identified, but there were no obvious examples of testi-
mony about the impact of cancer research from stake-
holders such as cancer patients or their families.
Lastly, despite the large number of examples identified 
from the previous literature, a minority of the empiri-
cal assessments used an impact framework. The Payback 
Framework, and an iteration of the CAHS Framework 
were used with success and these studies are excellent 
examples of how frameworks can be used for cancer 
research impact evaluation in future. Other frameworks 
identified from the literature (Additional file 2: Table S2) 
that may be appropriate for the assessment of cancer 
research impact  in future include Anthony Weiss’s logic 
model [75], the research impact framework [76] and the 
research utilisation ladder [77]. Weiss’s model is spe-
cific to medical research and encourages evaluation of 
how clinical trial publication results are implemented 
in practice and lead to health gain. He describes an effi-
cacy-efficiency gap [75] between clinical decision mak-
ers becoming aware of research findings, changing their 
practice and this having impact on health. The Research 
Impact Framework, developed by the Department of Pub-
lic Health and Policy at the UK London School of Hygiene 
and Tropical Medicine [76], is an aid for researchers to 
self-evaluate their research impact, and offers an extensive 
list of categories and indicators of research which could 
be applied to evaluating the impact of cancer research. 
Finally, Landry’s Research Utilisation Ladder [77] has 
similarities to the hierarchy used in the empirical study by 
Montegue and Valentim [68], and focuses on the role of 
the individual researcher in determining how research is 
utilised and its subsequent impact.
Reflecting on the strengths and limitations of the 
empirical approaches to cancer research impact identi-
fied in this study, Fig. 3 outlines recommendations for the 
future. One of these recommendations refers to improv-
ing the use of real-life data to assess the actual impact of 
research on incidence, treatment, and outcomes, rather 
than predicting these impacts by using clinical trial 
results. Databases for cancer incidence, such as SEER 
(USA) and the Office of National Statistics (UK), are 
relatively well established. However, those that collect 
data on treatments delivered and patient outcomes are 
less so, and when they do exist, they have been difficult 
to establish and maintain and often have large quantities 
of missing data [78, 79]. In their study, Glover et al. [67] 
specifically identified the lack of good quality data docu-
menting radiotherapy use in the UK in 2012.
The recommendations also suggest that impact assess-
ment for cancer and other health research could be made 
more robust by giving researchers access to cost data 
linked to administrative datasets. This type of data was 
used in empirical impact assessments performed in the 
USA [64, 66] because the existing Medicare and Medicaid 
health service infrastructure collects and provides access 
to this data. In the UK, hospital cost data is collected 
for accounting purposes but this could be unlocked as a 
resource for research impact assessments going forward. 
A good example of where attempts are being made to 
link resource use to cost data for cancer care in the UK is 
through the UK Colorectal Cancer Intelligence Hub [80].
Lastly, several empirical examples  highlighted that 
impact from cancer research can be increased when 
researchers or research organisations advocate, publi-
cise and help to interpret research findings for a wider 
audience [60, 72]. In addition, it is clear from these 
studies that organisations that want to evaluate the 
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impact of their cancer research must also appreciate 
that research impact evaluation is a multi-disciplinary 
effort, requiring the skills and input from individuals 
with different skill sets, such as basic scientists, clini-
cians, social scientists, health economists, statisticians, 
and information technology analysts. Furthermore, 
the users and benefactors from cancer research, such 
as patients and their families, should not be forgotten, 
and asking them which impacts from cancer research 
are important will help direct and improve future 
evaluations.
The strengths of this study are the broad, yet system-
atic approach used to identify existing reviews within 
the research impact literature. This allowed a more 
informed assessment of cancer research evaluations 
than would have been possible if a primary review of 
these empirical examples had been undertaken. Limi-
tations of the study include the fact that the review 
protocol was not registered in advance and that one 
researcher screened the full articles for review. The 
later was partly mitigated by using pre-defined inclu-
sion criteria.
Conclusions
Impact assessment is a way of communicating to funders 
and patients the merits of undertaking cancer research 
and learning from previous research to develop bet-
ter studies that will have positive impacts on society 
in the future. To the best of our knowledge, this is the 
first review to consider how to approach evaluation of 
the impact of cancer research. At the policy level, a les-
son learned from this study for institutions, govern-
ments, and funders of cancer research, is that an exact 
prescription for how to conduct cancer research impact 
evaluation cannot be provided, but a multi-discipli-
nary approach and sufficient resources are required if a 
meaningful assessment can be achieved. The approach 
to impact evaluation used to assess cancer research will 
depend on the type of research being assessed, the unit 
of analysis, rationale for the assessment and the resources 
Cancer research 
impact evaluaon 
Choose the methods of data collecon and 
analysis based on the raonale for assessment
(4As), unit of research being evaluated (for 
example, cancer centre vs clinical trial vs 
programme of research) and the categories of 
impact being assessed. The me and resources 
available, and the skill-set of the individuals 
performing the evaluaon will also be 
important. 
Do not dismiss unexpected impacts or negave 
impacts from cancer research– learning from
these will improve impact evaluaons and help 
to maximise impact from cancer research in 
future. If resources allow, consider assessing 
impacts from all categories (Figure 2), 
including those less well established for cancer 
research such as technological, cultural or 
wider economic impact. 
When assessing policy impact, consider
documents other than professional body 
clinical guidelines, and other mechanisms of 
policy impact such as agenda seng and 
implementaon. Be aware of the potenal 
me lag between the conduct of cancer 
research and likely impact. Acknowledge and 
account for this.
Avoid the use of inappropriate quantave 
metrics, not designed to assess the impact of 
cancer research, such as the journal impact 
factor. In parcular, avoid using these alone 
for allocaon of funding or promoon. Publish 
results of cancer research impact assessments 
to improve future evaluaons.
Consider using a research impact framework, 
especially if undertaking a mul-category 
assessment. The Payback framework is a 
seminal and enduring example, but others 
exist. The CAHS framework has been used 
successfully to evaluate the impact of a phase 
III clinical cancer trial. Suggesons for 
frameworks idenfied in part one of this study 
which may be suited to evaluang cancer 
research are provided in the main text. 
Consider the types of informaon required for 
the impact assessment in advance. The 
literature review by Thonon et al (2015) 
idenfied in part one of this study, included 
only one indicator of impact specific to cancer 
research. The same authors have since 
expanded on their review and conducted a 
study to understand which indicators are most 
appropriate for evaluang the impact of 
translaonal cancer research.1
Idenfy stakeholders for the cancer research 
being assessed and understand which impacts 
are important to them, and how research 
affects and benefits them. Stakeholders may 
include paents and their families, cancer 
funders or the government that oversees a 
public healthcare system. Methods for 
collecng data could include user tesmony, 
surveys, or interviews. 
Healthcare system and health impacts are 
likely to be important for cancer research 
impact evaluaon. Access to real life health or 
prescribing data can make these assessments 
more robust and will help policy makers 
evaluate the real-life benefits of invesng in 
cancer research. Making access to these 
datasets more feasible should be a priority for 
policy makers. Datasets that include real life 
costs for cancer care are also lacking. 
Fig. 3 Suggestions for approaching cancer research impact evaluation.  1ThononF, Boulkedid R, Teixeira M, Gottot S, Saghatchian M, Alberti 
C. Identifying potential indicators tomeasure the outcome of translational cancer research: a mixed methods approach. HealthRes Policy Syst. 
2015;13:72
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available. This study has added to an important dialogue 
for cancer researchers, funders and patients about how 
cancer research can be evaluated and ultimately how 
future cancer research impact can be improved.
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